GSK: welcomes reconsideration of decision in Zantac case
(CercleFinance.com) - GSK welcomes the Delaware Supreme Court's decision to reconsider the ruling allowing plaintiffs' expert evidence in the ranitidine trial.
GSK emphasizes that the scientific consensus shows no reliable evidence linking ranitidine to cancer risk, supported by 16 epidemiological studies.
The company pledges to defend itself vigorously while pursuing the litigation in parallel with the Supreme Court review. GSK also plans to present additional defenses in this context.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
GSK emphasizes that the scientific consensus shows no reliable evidence linking ranitidine to cancer risk, supported by 16 epidemiological studies.
The company pledges to defend itself vigorously while pursuing the litigation in parallel with the Supreme Court review. GSK also plans to present additional defenses in this context.
Copyright (c) 2024 CercleFinance.com. All rights reserved.